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A b s t r A c t
bAckground: Recent studies have suggested that the estrogen receptor alpha (ERα) 
gene is implicated in reduced bone mineral density (BMD). 
objective: In the present study, we investigated the relationship between genetic 
polymorphism in ΕRα 2014G-->A (T594T) (codon 594 G-->A) and osteoporosis in 
postmenopausal women.
Methods: A total of 59 postmenopausal women were included in the study (21 
normal, 24 osteoporotic, 14 osteopenic). The polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP) method was used to identify the ΕRα 
2014G->A polymorphism.
results: The three groups were found to be in genetic equilibrium. Also, there were 
no allele (p=0.578) and/or genotype frequencies (p=0.59) among the groups, i.e. the 
three groups could be treated as a genetically uniform population. As expected, nor-
mal women exhibited the highest BMD values (1.11 g/cm2) followed by the osteopenic 
(0.91 g/cm2) and the osteoporotic women (0.73 g/cm2). There was significant differ-
ence (p<0.05) in age only between the osteoporotic group (mean age 48.7 years) and 
either the normal (mean age 46 years) or the osteopenic group (mean age 45 years). 
No allele and/or genotype effect on BMD or age was detected. 
conclusion: Our results support the lack of association between ERα codon 594 
and BMD in postmenopausal women, since we found no allele and/or genotype effect 
on BMD or age. Further studies in a larger sample of postmenopausal women are 
needed to confirm our results.
i n t r o d u c t i o n
Recent studies have suggested that the estrogen receptor alpha (ERα) gene is impli-
cated in reduced bone mineral density (BMD). PvuII/XbaI polymorphisms located in 
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the first intron of the ERα gene have been shown to contribute 
to the determination of BMD in postmenopausal women.1 In 
our previous study, we investigated possible genetic alterations 
in exons 1 and 2 of ERα and its association to osteoporosis and 
familial osteoporosis in women and we found that the codon 10 
and codon 87 polymorphisms were not correlated with BMD 
and bone turnover markers.2 
In the present study, we focused on genetic alterations of 
the ligand binding domain (LBD) of ERα and particularly 
on the relationship, if any, between genetic polymorphism in 
ΕRα 2014G>A (T594T) and osteoporosis in postmenopausal 
women. 
M A t e r i A l s  A n d  M e t h o d s
s u b j e c t s
The population studied was all of Greek origin. They were 
divided into the following three groups: (1) 21 normal unre-
lated women aged 45.9±2.0 years, of postmenopausal status (1 
year after last menstrual period); (2) 24 unrelated women who 
were diagnosed as suffering from idiopathic postmenopausal 
osteoporosis, aged 48.7±2.7 years; and (3) 14 osteopenic 
subjects aged 45.0±2.8 years, who were also postmenopausal. 
The subjects were consecutive outpatients who visited the 
clinic for clinical evaluation and bone densitometry, at the 
endocrinology department of Laiko hospital in Athens. The 
study was developed in agreement with the policy statement of 
the Declaration of Helsinki and performed with the approval 
of the Committee on Biomedical Ethics of the University of 
Athens (Greece). Patients were defined as osteoporotic if they 
had a T-score less than -2.5 SD and osteopenic with T score 
values less than -1.0 and ≥2.5 SD.
Detailed medical histories were obtained from each par-
ticipant and none of the women reported hyperthyroidism, or 
endogenous/exogenous hypercortisolism, diabetes or any other 
systemic illness known to affect BMD. They also underwent 
clinical and biochemical evaluation to exclude other secondary 
causes of osteoporosis.
b o n e  M i n e r A l  d e n s i t y  s t u d y
Bone mineral density (g/cm2) was measured at the lumbar 
spine (L2–L4) by dual energy X-ray absorptiometry (DEXA). 
The measurements were made using a Norland Xr 26 (Norland 
Medical Systems Inc., White Plains, N.Y., USA) instrument, 
with standards from a Greek population. T scores and age-
matched comparisons (Z scores) were also calculated using 
the installed software of the apparatus.
s A M p l e  c o l l e c t i o n  A n d  d e t e r M i n A t i o n 
o f  Ε R α  G 2 0 1 4 A  ( T 5 9 4 T )
Venous blood (5 mL) from 59 patients was collected and 
DNA was prepared as previously described. Oligonucleotide 
primers (forward: 5΄-CGCCCGCCG CGCCCCGCGCCCG-
GCCCGCCGCCCCCGCCCGCTGTGTCTTCCCACCTA-
CAG-3΄, reverse: 5΄-CGTGTGGGAGCCAGGGAGCT- 3΄) 
were prepared to amplify the coding region of exon 8 manually, 
as previously described.3 
Polymerase chain reaction (PCR) product was digested 
with restriction endonuclease BtgI (PCR- RFLPs: Restric-
tion fragment length polymorphism). The ERα genotype of 
the DNA samples was identified by electrophoresis in 3 % 
agarose gels. The ACA/ACA genotype appeared as 227bp 
bands on agarose gel electrophoresis, ACG/ACG appeared 
as two bands of 129bp and 98bp and ACG/ACA appeared 
on all these bands. At least 10 % of the samples belonging to 
unselected samples was studied twice in order to exclude the 
digestion errors.
s t A t i s t i c A l  A n A ly s i s
First, the allele frequencies per group were estimated. Stan-
dard errors (SE) of the allele frequencies were also calculated, 
assuming a binomial distribution, as SE(p)=sqrt(pq/2N) where 
p, q is the frequency of alleles ΑCG και ACA, respectively 
and Ν the sample size. Examination for Hardy-Weinberg 
equilibrium (HWE) followed using the Genepop software.4 
Age, as well as BMD were subjected to ANOVA fitting alleles 
or genotypes as the only fixed effect. During BMD analysis, 
age was additionally fitted as a covariate. Results of ANOVA 
are presented as least squares means (with SEs). During mul-
tiple means contrasts, the Bonferroni correction for p-values 
adjustment was employed. All these analyses were carried out 
by SAS (ver 9.0) software.
r e s u l t s
According to the HWE test the three groups were found 
to be in genetic equilibrium (Table 1). In addition, there were 
no allele (p=0.578) and/or genotype frequencies (p=0.59) 
between groups (both cases, G-like test). This would mean 
that the three groups could be treated as a genetically uniform 
population. Table 2 shows the genotype distribution per group 
(normal, osteopenic and osteoporotic). Table 3 shows the least 
squares means of age and BMD per group. As it was expected, 
the normal women exhibited the highest BMD values (1.11 
g/cm2) followed by the osteopenic (0.91 g/cm2) and the oste-
oporotic women (0.73 g/cm2). There was significant difference 
(p<0.05) in age only between the osteoporotic group (mean 
age 48.7 years) and either the normal (mean age 46 years) or 
the osteopenic group (mean age 45 years) (Table 3). Table 4 
shows the least squares means (± SE) of BMD and age per 
allele and genotype. As it is shown, we detected no allele and/
or genotype effect on BMD or age.
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tAble 3. Least squares means (± SE) of age and bone 
mineral density (BMD) per group
group n Age (years) ΒΜD (gr/cm2)
Normal 21 45.9
a
 ± 2.0 1.11 ± 0.02
Osteoporotic 24 48.7
b
 ± 2.7 0.73 ± 0.02
Osteopenic 14 45.0
a
 ± 2.8 0.91 ± 0.03
Means per group with different superscripts are significantly different 
(p<0.05).
TAble 4. Least squares means (± SE) of BMD and age per allele and genotype 
Allele n ΒΜD (gr/cm2) Age (years) Genotype n ΒΜD (gr/cm2) Age (years)
ACG 87 0.90 ± 0.02 47.9 ± 1,1 ΑCA/ACA 5 0.90 ± 0.08 43.8 ± 2.3
ACA 19 0.90 ± 0.04 43.8 ± 2,5 ACG/ACA 9 0.89 ± 0.06 43.9 ± 3.6
ACG/ACG 39 0.91 ± 0,. 48.3 ± 1.7
BMD = bone mineral density.
TAble 1. Allele frequency per group and p-value of the test for Hardy-Weinberg equilibrium 
Alleles
2N group αCG n AcA n p-value
42 Normal 0.79 ± 0.06 33 0.21 ± 0.06 9 0.195
48 Osteoporotic 0.83 ± 0.05 40 0.17 ± 0.05 8 0.09
28 Osteopenic 0.89 ± 0.06 25 0.11 ± 0.06 3 0.111
n: number of alleles.
TAble 2. Genotype distribution per group
Genotypes
group ACG/ACG ACG/ACA ACA/ACA Total
Νοrmal 14 5 2 21
Osteoporotic 18 4 2 24
Osteopenic 12 1 1 14
Total 44 10 5 59
d i s c u s s i o n
Estrogen seems to play an important role in maintaining 
normal bone turnover. The estrogen receptor alpha (ERα) 
gene appears to be the major estrogen receptor mediating 
estrogen action in all the three types of bone cells and in addi-
tion to several other genes has been implicated as a candidate 
in the genetic basis of osteoporosis.5 The human ERα gene is 
located on chromosome 6p25.1, comprises eight exons, and 
spans more than 140 kb.
Interestingly, Tural et al investigating recently the associa-
tion between osteoporosis and ERα 397 T>C polymorphism 
in postmenopausal women, found no statistically significant 
difference in the genotype and allele frequencies of patients 
and controls, however, the ERα CC genotype compared 
with TT+TC genotypes was found to increase two-fold the 
risk of osteoporosis.6 Moreover, Erdogan et al, studying the 
relationship among bone mineral density (BMD) values of 
lumbar vertebra and femoral neck and ERα gene PvuII and 
XbaI polymorphisms in intron 1, found that ERα gene PvuII 
polymorphism was effective on average lumbar vertebra BMD 
value in postmenopausal women.7 In the same line, other stud-
ies in Korean and Turkish postmenopausal women confirmed 
that the ER PvuII and XbaI polymorphisms were associated 
with BMD in lumbar spine and femoral neck.8,9 
Codon 594 is a silent mutation in the ligand binding domain 
(AF-2) of ERα, thus it does not alter the protein; however, it 
may affect gene expression via the sequence change in RNA 
influencing ERα gene transcription, processing or translation, 
thus resulting in different reactions to estrogens. Indeed, a 
change in synonym codons might call for a different tRNA 
to respond, influencing therefore the efficiency of translation 
and receptor protein expression.10 Moreover, the codon 594 
polymorphism may be linked with a ‘causal’ variant in the im-
mediate vicinity of the ERα gene itself or another unidentified 
gene nearby.
Several studies have been conducted investigating the 
relationship between codon 594 polymorphism and various 
diseases. Breast cancer, migraine, knee osteoarthritis, systemic 
lupus erythematosus and renal cancer have been associated with 
the presence of codon 594 polymorphism.11-14 To our knowl-
edge, this is the first study on a possible association between 
codon 594 polymorphism and postmenopausal osteoporosis. 
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Although there were age differences among the three groups 
studied (normal/ osteopenic and osteoporotic), all women 
were in post-menopausal status. Moreover, no statistical sig-
nificance in the mean duration of post-menopausal status was 
observed among the three groups. The main limitation of this 
preliminary study is the small number of participants leading 
in a statistical power equal to 0.1.
c o n c l u s i o n
Our results support the lack of association between ERα 
codon 594 and bone mineral density (BMD) in postmenopausal 
women, since we found no allele and/or genotype effect on 
BMD or age. Further studies in larger sample sizes are needed 
to confirm our results.
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